Digest Network Come funziona
Network
/
Società
Au
Non verificato

Aulos Bioscience

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

11 comunicati stampa

Guarda tutti i comunicati
07/11/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
New Phase 2 Data for Aulos Bioscience’s Imneskibart Reveal Clinical Activity in Melanoma and Non-Small Cell Lung Cancer
Fonte
Aulos Bioscience
Emittente
Business Wire
1.00
0
03/10/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Industria
Aulos Bioscience to Present Updated Phase 2 Data for Imneskibart (AU-007) in Melanoma and Non-Small Cell Lung Cancer at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Fonte
Aulos Bioscience
Emittente
Business Wire
1.00
0
29/04/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Aulos Bioscience Presents New Phase 2 Data for AU-007 Demonstrating Continued Strong Anti-Tumor Activity in Advanced Cancers at AACR Annual Meeting
Fonte
Aulos Bioscience
Emittente
Business Wire
1.00
0
14/04/2025
Industria
Oncologia
Salute
Tecnica
Medicina - Varie
Farmaceutica
Biotecnologia
Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating AU-007 in Combination With Nivolumab for Second-Line Treatment of Melanoma
Fonte
Aulos Bioscience
Emittente
Business Wire
1.00
0
25/03/2025
Eventi
Scienza
Tecnica
Medicina - Varie
Biotecnologia
Farmaceutica
Salute
Oncologia
Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic AU-007 in Melanoma at AACR Annual Meeting
Fonte
Aulos Bioscience
Emittente
Business Wire
1.00
0
27/11/2024
Industria
Oncologia
Salute
Tecnica
Medicina - Varie
Farmaceutica
Biotecnologia
Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating the Combination of Avelumab and AU-007 for the Treatment of Non-Small Cell Lung Cancer
Fonte
Aulos Bioscience
Emittente
Business Wire
1.00
0
07/11/2024
Eventi
Industria
Tecnica
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
Strong Evidence of AU-007’s Anti-Tumor Activity in Advanced Solid Tumor Cancers Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Fonte
Aulos Bioscience
Emittente
Business Wire
1.00
0
07/11/2024
Eventi
Industria
Tecnica
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
SITC: Aulos Bioscience Presents Strong Evidence of AU-007’s Anti-Tumor Activity
Fonte
Aulos Bioscience
Emittente
Business Wire
1.00
0
23/10/2024
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Aulos Bioscience Presents Phase 2 Dose Selection Data for Novel IL-2 Therapeutic Antibody, AU-007, at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Fonte
Aulos Bioscience
Emittente
Business Wire
1.00
0
09/10/2024
Eventi
Fiere
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Aulos Bioscience Announces Presentation Detailing Phase 2 Dose Selection for AU-007 in Solid Tumor Treatment at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Fonte
Aulos Bioscience
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0